Physostigmine
- Generic Name
- Physostigmine
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C15H21N3O2
- CAS Number
- 57-47-6
- Unique Ingredient Identifier
- 9U1VM840SP
- Background
A cholinesterase inhibitor that is rapidly absorbed through membranes. It can be applied topically to the conjunctiva. It also can cross the blood-brain barrier and is used when central nervous system effects are desired, as in the treatment of severe anticholinergic toxicity.
- Indication
For the treatment of glaucoma, and in the treatment of severe anticholinergic toxicity.
- Associated Conditions
- Anticholinergic Syndrome
- Associated Therapies
- -
Treatment of Adolescent Antimuscarinic (Anticholinergic) Toxidrome
- First Posted Date
- 2017-03-27
- Last Posted Date
- 2021-08-23
- Lead Sponsor
- University of Colorado, Denver
- Target Recruit Count
- 19
- Registration Number
- NCT03090620
- Locations
- 🇺🇸
University of Colorado Anschutz Medical Campus, Children's Hospital Colorado, Aurora, Colorado, United States
Anticholium® Per Se
- Conditions
- Interventions
- First Posted Date
- 2017-01-06
- Last Posted Date
- 2018-01-29
- Lead Sponsor
- University Hospital Heidelberg
- Target Recruit Count
- 20
- Registration Number
- NCT03013322
- Locations
- 🇩🇪
University Hospital Heidelberg, Heidelberg, Baden-Württemberg, Germany
Evaluation if Physostigmine Reduces Symptoms in Patients Who Has Developed a Delirium in Intensive Care After a Surgery
- First Posted Date
- 2014-08-13
- Last Posted Date
- 2017-03-10
- Lead Sponsor
- PD Dr. Bertram Scheller
- Target Recruit Count
- 120
- Registration Number
- NCT02216266
- Locations
- 🇩🇪
Department of Anesthesiology, Intensive-Care Medicine and Pain Therapy, Frankfurt, Hessia, Germany
Acetylcholine, Tobacco Smoking, Genes and Nicotinic Receptors
- First Posted Date
- 2013-12-11
- Last Posted Date
- 2023-10-25
- Lead Sponsor
- Yale University
- Target Recruit Count
- 80
- Registration Number
- NCT02008292
- Locations
- 🇺🇸
Yale Magnetic Resonance Research Center, New Haven, Connecticut, United States
🇺🇸Yale PET Center, New Haven, Connecticut, United States
🇺🇸Connecticut Mental Health Center, New Haven, Connecticut, United States
Pilot Study of Physostigmine-Enhanced Opioid Analgesia
- First Posted Date
- 2011-07-14
- Last Posted Date
- 2012-02-22
- Lead Sponsor
- Medical University of Graz
- Target Recruit Count
- 20
- Registration Number
- NCT01394445
- Locations
- 🇦🇹
Hospital of the Medical University of Graz, Graz, Styria, Austria
Phamacological Reversal of Airway Instability During Sedation
- Conditions
- Interventions
- First Posted Date
- 2010-07-28
- Last Posted Date
- 2015-04-27
- Lead Sponsor
- University of Rochester
- Target Recruit Count
- 10
- Registration Number
- NCT01171118
- Locations
- 🇺🇸
University of Rochester Medical Center, Rochester, New York, United States
The Effect of Physostigmine on Cognitive Functioning in the Immediate Period After Sedation for Colonoscopy
- First Posted Date
- 2010-05-12
- Last Posted Date
- 2010-05-12
- Lead Sponsor
- Rabin Medical Center
- Target Recruit Count
- 160
- Registration Number
- NCT01121497
- Locations
- 🇮🇱
Hasharon Hospital, Rabin Medical Center, Petah Tiqva, Israel
Physostigmine After General Anesthesia
- Conditions
- Interventions
- First Posted Date
- 2009-02-25
- Last Posted Date
- 2010-05-27
- Lead Sponsor
- Bispebjerg Hospital
- Target Recruit Count
- 50
- Registration Number
- NCT00850850
- Locations
- 🇩🇰
Bispebjerg Hospital, Copenhagen, Copenhagen NV, Denmark
Pharmacological Intervention in Insulin Resistance Targeting Autonomic Nerve Activity
- Conditions
- First Posted Date
- 2008-06-03
- Last Posted Date
- 2009-03-13
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 12
- Registration Number
- NCT00689208
- Locations
- 🇸🇪
Research Site, Göteborg, Sweden
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.